Research programme: spinal cord injury and cancer therapies - Renovis/Genentech

Drug Profile

Research programme: spinal cord injury and cancer therapies - Renovis/Genentech

Alternative Names: Nerve regeneration/anti-angiogenesis programme; Spinal cord injury therapies research programme - Renovis

Latest Information Update: 29 Jun 2009

Price : $50

At a glance

  • Originator Renovis
  • Developer Genentech; Renovis
  • Class Proteins; Small molecules
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Brain injuries; Cancer; Spinal cord injuries

Most Recent Events

  • 03 May 2008 Renovis has been acquired by Evotec AG
  • 31 Oct 2005 Renovis and Genentech are in discussions about the future of this programme
  • 15 Dec 2003 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top